CSNK2B and neoplasm: Taken together, these results suggest that the administration of CK2B knockdown or CK2 inhibitors contribute to delaying the adoptive CD8+ T‐cell exhaustion and enhances the efficacy of anti‐PD‐1 therapy in both draining LNs and tumor tissues.